

# Subject Index, 1988

## Vol. 38, Nos. 1-6

### A

**Acetaminophen**, 334, 336-337

**ACTH (adrenocorticotrophic hormone)** as tumor-derived marker, 105

**Adjuvant analgesics**, 333, 344, 346

Anticonvulsants, 344

Antidepressants, tricyclic, 344

Corticosteroids, 346

Neuroleptics, 344

**Adolescents**

And cigarette smoking, prevention, 207-209

And smokeless tobacco use, 226-229

**Adrenocorticotrophic hormone** (See, ACTH)

**AFP (alpha-fetoprotein)**, 105-109, 112, 366

**American Cancer Society**

Checkup guidelines (change), 127

75th anniversary (editorial), 2-4

**Amines, aromatic, and bladder cancer**, 213

**Amitriptyline**, 344

**Analgesics** (See, Pharmacologic approaches to cancer pain management; specific analgesics)

**Anesthetic approaches to cancer pain management**, 346-347

**Anger, and breast cancer**, 151-152

**Announcements**

Proceedings available (Workshop on Psychosexual and Reproductive Issues), 145  
UICC fellowships, 320

**Antibodies**

Chimeric, 79

Monoclonal, 77-80, 108

Murine, 68, 79, 86

**Anticonvulsants**, 344

**Antidepressants, tricyclic**, 135, 344

**Anxiety, relief of during cancer therapy**, 133-134

**Asbestos exposure and lung cancer**, 26  
And synergistic effect of cigarette smoking, 26

**Aspirin**, 336-337

**Author's Correction** (Erratum), 126

**Azimexon**, 72

### B

**Bacillus Calmette Guérin** (See, BCG)

**Baclofen**, 344

**BCG**, 68, 71-72

**Behavioral approaches to treatment-related distress**, 138-145

Case report, 142-143

Clinical considerations, 143-144

And fear of medical procedures, 141

And nausea and vomiting, anticipatory, 138-141

**Benzodiazepines**, 134

**Betel quid chewing**, 242

**Biliary bypass and pancreatic cancer**, 314

**Biliary passages, cancer of**, 48, 52

**Biologic response modifiers**, 68

**Biotechnology and development of vaccines**, 98-102

**Biotransformation and oral medication**, 323

# Subject Index, 1988

## Vol. 38, Nos. 1-6

### A

**Acetaminophen**, 334, 336-337

**ACTH (adrenocorticotrophic hormone)** as tumor-derived marker, 105

**Adjuvant analgesics**, 333, 344, 346

Anticonvulsants, 344

Antidepressants, tricyclic, 344

Corticosteroids, 346

Neuroleptics, 344

**Adolescents**

And cigarette smoking, prevention, 207-209

And smokeless tobacco use, 226-229

**Adrenocorticotrophic hormone** (See, ACTH)

**AFP (alpha-fetoprotein)**, 105-109, 112, 366

**American Cancer Society**

Checkup guidelines (change), 127

75th anniversary (editorial), 2-4

**Amines, aromatic, and bladder cancer**, 213

**Amitriptyline**, 344

**Analgesics** (See, Pharmacologic approaches to cancer pain management; specific analgesics)

**Anesthetic approaches to cancer pain management**, 346-347

**Anger, and breast cancer**, 151-152

**Announcements**

Proceedings available (Workshop on Psychosexual and Reproductive Issues), 145

UICC fellowships, 320

**Antibodies**

Chimeric, 79

Monoclonal, 77-80, 108

Murine, 68, 79, 86

**Anticonvulsants**, 344

**Antidepressants, tricyclic**, 135, 344

**Anxiety, relief of during cancer therapy**, 133-134

**Asbestos exposure and lung cancer**, 26  
And synergistic effect of cigarette smoking, 26

**Aspirin**, 336-337

**Author's Correction** (Erratum), 126

**Azimexon**, 72

### B

**Bacillus Calmette Guérin** (See, BCG)

**Baclofen**, 344

**BCG**, 68, 71-72

**Behavioral approaches to treatment-related distress**, 138-145

Case report, 142-143

Clinical considerations, 143-144

And fear of medical procedures, 141

And nausea and vomiting, anticipatory, 138-141

**Benzodiazepines**, 134

**Betel quid chewing**, 242

**Biliary bypass and pancreatic cancer**, 314

**Biliary passages, cancer of**, 48, 52

**Biologic response modifiers**, 68

**Biotechnology and development of vaccines**, 98-102

**Biotransformation and oral medication**, 323

**Bladder, cancer of, 213-223**

- Classification, 214
- Clinical staging, 214-216
- Diagnosis, 213-214
- Future prospects, 220-221
- Incidence and epidemiology, 7, 14, 213
- Mortality of, 9, 15, 52
- And schistosomiasis, 213
- Survival rates for, by race, 6, 22
- Treatment and results, 216-220
  - Metastatic tumors, 220
  - Muscle-infiltrating tumors, 216, 218-220
  - Superficial tumors, 216-218

**Bone cancer**

- Incidence of, 14
- Mortality of, 9, 15
- And neutron irradiation, 354-355, 358-359
- Survival rates for children, 21

**Brain and central nervous system cancer**

- Incidence of, 14
- Mortality of, 9, 15
- Survival rates for children, 21
- Survival rates for, by race, 22

**Breaking Free (ACS anti-smoking program), 209****Breast cancer, 146-161, 291-309, 368-371**

- ACS guidelines for detection of, in asymptomatic women, 293
- Body image and treatment of, 156-157
- And breast preservation, 154-155
- And breast reconstruction, 154
- And depression, postmastectomy, 154, 156
- Imaging in, 61 (correction)
- Incidence of, 5, 7, 14, 16
- And interferon therapy, 268
- And irradiation, effects of on, 368-371
- And mammography screening pilot project (television-promoted), 291-309
- Marital relations and, 149-152, 155
- And mastectomy, 154-155
- Mortality of, 5, 9, 12, 15, 17, 19
- And most-significant-other in care of patient, 146-153
- And double-bind communication, 149-152
- And emotional assault of breast cancer, 148
- Identifying, 146-147
- And office intervention, 151-152
- And patient's emotional category, 147
- And physician evaluation of patient, 147
- Role of, 148-149
- And multicentricity, 371
- Radiography, 61 (correction)
- Sexual and intimate consequences of treatment, 154-161
- Survival rates for, by race, 6, 22

**Bronchogenic cancer, 37, 39, 41-43, 46-47**

- Survival rates for, by race, 22

**Buprenorphine, 337****Butorphanol, 337****C**

---

**CA-125, as tumor marker, 114-115****CA 19-9, as tumor marker, 115****California Self-Help Center, 164****Cancer control and smoking cessation, 196**

- (See also, Smoking, Cigarette, and the need for action by health professionals)

**Cancer Prevention Study I, 25****Candlelighters Childhood Cancer Foundation, 169****Carcinoembryonic antigen (See, CEA)****CEA (carcinoembryonic antigen), 105-108, 112-115****Central nervous system (See, Brain and central nervous system cancer)****Cerebral vascular lesions, 30-34, 54, 57****Cervical cancer**

- ACS new checkup guidelines, 127-128
- Incidence of, 7, 14
- Irradiation for, and increased risk of bladder cancer, 213
- Mortality of, 15
- Survival rates for, by race, 6, 22

**Chemotherapy**

- Analgesic response to, 333
- And bladder tumors, 220-221
- Interferon combined with, 270-273
- And nausea and vomiting, anticipatory, 138-140
- And pancreatic cancer, 315-316
- And sacrococcygeal teratomas, 365-366

**Chewing tobacco (See also, Smokeless tobacco)**

**Chicago Self-Help Center, 164**

**Children**

- Cancer in, survival rates by site, 21
- And cigarette smoking prevention, 206-210
- And distress during cancer treatment, behavioral approaches for, 141-142
- Mortality, leading causes of among, 20
- Parent self-help groups for families of children with cancer, 169-175
- And smokeless tobacco, use of, 227-229

**Cholangiopancreatography, endoscopic retrograde (ERCP)**

- In pancreatic cancer, 311

**Choline magnesium trisalicylate, 336**

**Circulatory system, diseases of**

- And smoking, 30-35, 48-50, 53-54, 57

**Cisplatin, 139**

**Classics in oncology**

- E. Cuyler Hammond, ScD, 23-27
- In praise of a prepared mind: A retrospective on Jean Lindenmann, 278-279
- Remarks on smoking: Evidence and ethics, 59-60
- Smoking and death rates—Report on forty-four months of follow-up of 187,783 men, 28-58
- Viral interference: I. The interferon, 280-290

**Clomipramine, 344**

**Cocaine, 346**

**Codeine, 337**

**Colon, cancer of, 108, 113, 268**

- Incidence of, 5, 7, 14, 16
- Mortality of, 5, 9, 12, 13, 15, 17, 18
- Smoking and, 48, 52
- Survival rates for, by race, 6, 22

**Compassionate Friends (self-help group), 167**

**Computerized tomography (CT) and pancreatic cancer, 311**

**Condylomata acuminata, 268**

**Connective tissue cancer**

- Incidence of, 14
- Mortality of, 9, 15

**Coronary artery disease, 30-34, 49-50, 53-54, 57**

**Corrections**

- Digital breast radiography, 61
- Laser treatment of patients with condylomata and squamous carcinoma precursors of the lower female genital tract, 126 (Erratum; Author's correction)
- Pruritus, 61

**Corticosteroids, 346**

**C. parvum, 71, 72**

**Cyclophosphamide, 72**

**Cystectomy, and bladder tumors, 218-219**

---

**D**

**Deafferentation, 329**

**Delirium, and cancer therapy, 135-136**

**Dentists, role of in treatment of cancer patient, 62-64 (letter)**

**Depression**

- And cancer therapy, 136
- Postmastectomy, 154, 156

**Dexamethasone, 346**

**Dextroamphetamine, 341, 346**

**Diets, as unproven cancer treatments, 180-181**

**Diffunisal, 336**

**Digestive system, cancer of, 14-15**  
(See also, specific digestive organs)  
Smoking and, 38-41, 43, 44, 48, 52

**Diphenhydramine, 135**

**Distraction technique for control of anticipatory nausea and vomiting, 141**

**Distress, treatment-related (See also, Behavioral approaches to treatment-related distress)**

**DNA**

- Neutrons and photons effects on, 353, 357, 360
- Viral, and genetic engineering, 100
- Viral, and snuff-induced viral inactivation, 249, 251-254

**Double-blind communication (projective identification), and the cancer patient, 149-152**

**Doxepin**, 344

**Doxorubicin**, 72

---

## E

**Ear, cancer of**, 187-189 (letters)

**Editorial**

The American Cancer Society: 75 years,  
2-4

**Emotive imagery technique and fear of  
medical procedures**, 142

**Endocrine glands, cancer of**, 14-15

**Endoscopic retrograde  
cholangiopancreatography (ERCP)**, 311

**Endoscopic treatment for bladder tumors**,  
216, 218

**Epidermoid carcinomas and  
adenocarcinomas, and neutron irradiation**,  
354

**Erratum** (Author's correction), 126

**Esophagus, cancer of**

Incidence of, 7, 14  
Mortality of, 13, 15  
And smokeless tobacco, use of, 240  
Survival rates for, by race, 6, 22

**Ethics and smoking**, 59-60

**Eukaryotic cells and systems (lower and  
higher)**, 98-99

**Ewing's sarcoma**

Survival rates for children, 21

**Eye, cancer of**, 14-15

---

## F

**Feedback**

Coping with problems related to cancer  
and cancer treatment, 61-64

Correction, 61

Ear, cancer of, 187-189

Imaging and cancer, 189-190

Penis, cancer of, 191-192

Sexual response and cancer, 190-191

**Flossing, dental, and thrombocytopenia**,  
62-64 (letter)

---

## G

**Gallbladder, cancer of**, 48, 52

**Gastrointestinal tract**

(See also, specific gastrointestinal organs)  
Neutron irradiation and, 355

**Genetic engineering of genomes and  
attenuation of viruses**, 100

**Genital organs, cancer of**, 14-15

(See also, specific genital organs)  
And smoking, 38-41, 43, 44, 48, 52

**Gingival recession, and smokeless  
tobacco use**, 232, 234

---

## H

**HBLV (human B-cell leukemia virus)**, 96

**HBV (hepatitis B virus)**, 95, 97

**HCG (human chorionic gonadotropin)**,  
105-106, 108-112

**HCMV (human cytomegalovirus)**, 96

**Head and neck, cancer of, and neutron  
irradiation**, 354, 356-357

**Health Consequences of Involuntary  
Smoking** (Surgeon General's report, 1986),  
194

**Heart diseases**

Smoking and, 30-35, 48-50, 53-54, 57

**Hematopoietic system, smoking and**,  
38-41, 43, 52

**Hepatitis B virus** (See, HBV)

**Herpesviruses** (See, HSV)

**HLAs (human lymphocyte antigens)**, 259,  
262

**Hodgkin's disease**

Incidence, 14

Mortality of, 9, 15, 48, 52

Survival rates for children, 21

Survival rates for, by race, 22

**Holistic medicine (naturopathy), 183**

**Hormones, postmenopausal replacement, and the breast cancer patient, 158**

**HPV (human papilloma virus), 95-96, 232**

**HSV (Herpes simplex virus), 96**  
And snuff-induced viral inactivation,  
248-256

**HTLV (human T-cell leukemia virus), 95-98**

**Human chorionic gonadotropin (See, HCG)**

**Human lymphocyte antigens (See, HLAs)**

**Human papilloma virus (See, HPV)**

**Human T-cell leukemia virus (See, HTLV)**

**Hydrocodone, 337**

**Hydromorphone, 338**

**Hydroxyzine, 346**

**Hyperthermia with chemotherapy and pancreatic cancer, 317**

**Hypnosis, use of, and fear of medical procedures, 142**

**Hypophysectomy**  
And reduction of pain in disseminated  
cancer, 348

---

## I

**Ibuprofen, 336**

**IL-2 (See, Interleukin-2)**

**Imaging in cancer, 189-190 (letters)**  
In breast cancer (correction), 61

**Imipramine, 344**

**Immunology and cancer, 66-126 (See also, Interferon, Interleukin-2)**  
Future prospects of immunologic  
treatment, 86, 88-89  
Immunotherapy, 68-94  
Active, 68-69, 71-78, 81  
Passive, 69, 77-86  
And tumor markers, 104-126  
And viral infections, immunization against,  
95-103

**Immunostimulants, 71-72**

**Interferon, 258-277; 278-279; 280-290 (classic)**

Administration of (studies), 72-73  
Chemotherapy and, 270-272  
Description of, 258-259  
Immunology and, 68-70, 72-73, 259  
Role of in cancer therapy, 258-277  
Clinical responses, 262-273  
Modes of action, 259-262  
Toxicity, 273  
Virus interference and, 280-290 (classic)

**Interleukin-2, 68**

Administration of (studies), 73-78  
Future prospects, 86, 88-89  
And transferred LAK and tumor-specific  
T-cells (studies), 80-87

**Iridology, 180-181**

**Isoprinostine, 72**

---

## K

**Kaposi's sarcoma, 265-266**

**Keratinization, and smokeless tobacco use, 231-232**

**Kidney, cancer of**

And cigarette smoking, 52  
Incidence of, 14  
Mortality of, 15  
Survival rates for children, 21  
Survival rates for, by race, 22

---

## L

**LAK cells (lymphokine-activated killer cells), 68**

And interferon, 259  
And interleukin: 2, 73-75, 77, 79, 80-89

**Larynx, cancer of**

Incidence of, 14  
Laryngeal papillomas and interferon, 268  
Mortality of, 15  
Smoking and, 38-41, 43, 44, 51, 56  
Survival rates for, by race, 22

**Laser treatment of patients with condylomata and squamous carcinoma precursors, 126 (Author's correction)**

**L-dopa, 346**

**Lentinin, 72**

**Letters to the editor (See, Feedback)**

## **Leukemias**

- Granulocytic, acute, 21
- Hairy cell, 72, 262-263, 273
- Incidence of, 5, 14, 16
- Interferon and, 262-263, 266, 273
- Lymphocytic, acute, 21
- Monocytic, 14, 15, 262
- Mortality of, 5, 9, 12, 13, 15, 17, 19, 48, 52
- Survival rates for children, 21
- Survival rates, by race, 22

## **Levamisol, 72**

## **Levorphanol, 338**

## **Lip, cancer of**

- Smoking and, 38-41, 43, 44, 51, 56

## **Liver, cancer of**

- Cirrhosis of, 31, 33-34, 55, 57
- Incidence of, 7, 14
- Mortality of, 12, 13, 15
- Smoking and, 48, 52
- Survival rates for, by race, 6, 22

## **L-tryptophan, 346**

## **Lung cancer**

- Asbestos exposure and, 26
- And synergistic effect of cigarette smoking, 26
- Incidence of, 5, 7, 14, 16
- And interferon, 268
- Mortality of, 5, 9, 12, 13, 15, 17, 19
- Smoking and, 24-26, 37-47, 50, 56-57
- Survival rates for, by race, 6, 22

## **Lymphatic system, smoking and, 38-41, 43, 52**

## **Lymphokine-activated killer cells (See, LAK cells)**

## **Lymphomas, Non-Hodgkin's**

- (See also, Hodgkin's disease)
- Incidence of, 5, 14
- Mortality of, 5, 9, 15
- Survival rates for children, 21
- Survival rates, by race, 22

## **Lymphosarcoma, 48, 52**

## **M**

## **Macrobiotic diet, 180**

## **Mammography screening pilot project (television-promoted) 291-309**

## **Marital relations and breast cancer patients, 148-152, 154-161**

## **Mastectomy, 154**

- Depression and, 154, 156

## **Maternity, and breast cancer, 155**

## **Medical procedures, fear of, 141-142**

## **Megavitamins, as unproven cancer treatment, 181**

## **Melanoma**

- Incidence of, 5, 7, 14, 16
- Interferon and, 266, 268-269, 272
- Mortality, 5, 9, 15, 17
- Survival rates for, by race, 6, 22

## **Mended Hearts (self-help group), 165, 167**

## **Mental imagery, as unproven cancer treatment, 181**

## **Meperidine, 337-338**

## **6-Mercaptopurine, 72**

## **Metabolic therapy, as unproven cancer treatment, 176, 179, 180**

## **Metaclopramide, 341**

## **Methadone, 338, 340**

## **Methotrimeprazine, 344**

## **Methylphenidate, 341, 346**

## **Methylprednisolone, 346**

## **Morphine, 323, 338**

## **Mortality, 28-58, 59-60 (classics) (See also, specific sites)**

- Cancer, age-adjusted rates for selected sites (US, 1930-1985), 12-13
- Cancer, around the world, age-adjusted (1982-1983), 18-19
- Cancer, estimated for all sites (US, 1988), 5, 15, 17
- Cancer, by site, sex, and age group (US, 1985), 9
- For leading causes of death (US, 1985), 8, 10-11
- For leading causes of death among children (US, 1985), 20
- Smoking and, 24-25, 28-58 (classic), 59-60 (classic)

## **Most-significant-other (See also, Breast cancer, Most-significant-other in care of patient)**

**Motivation, positive, and fear of medical procedures, 141-142**

**Mouth, cancer of**

- Incidence of, 14
- Mortality of, 15
- Smokeless tobacco and, 224-225
- Smoking and, 38-41, 43, 44, 51, 56

**Myeloma, multiple, 48, 52**

- Incidence of, 14
- Interferon and, 262, 264, 266
- Mortality of, 15
- Survival rates for, by race, 22

## **N**

**Nalbuphine, 337**

**Naloxone, 341**

**Naproxen, 336**

**Narcotics and cancer pain control, 322-326**

- (See also, Opioid analgesics; Pain control in the cancer patient; Pharmacologic approaches to cancer pain management)

**Nausea and vomiting, anticipatory, 138-139**

- Causes of, 139-140
- Control of, techniques for, 140-141

**Neck (and head) cancer and neutron irradiation, 354, 356-357**

**Neopterin, as tumor marker, 116**

**Neuroaugmentative approaches to cancer pain management, 347**

**Neuroblastoma, 113**

- (See also, NSE)

**Neuroleptics, 344**

**Neuron-specific enolase (See NSE)**

**Neurosurgical approaches to cancer pain management, 347-348**

**Neutron beam therapy in management of locally advanced nonresectable radioresistant tumors, 353-361**

- (See also, Radiotherapy)

**Nicotine**

- Health consequences of exposure to, 245-247
- Pharmacology of, 244
- And smokeless tobacco use, 244-245

**NK (Natural Killer) cell, 259, 262**

**Nociception, nociceptive focus, 327-329**

**Nonresectable radioresistant tumors and neutron beam therapy, 353-361**

**Nonsteroidal anti-inflammatory drugs (NSAIDs), 333-336**

- Ceiling dose, 336
- Guidelines for drug selection and dosing, 334-336

**NSE (neuron-specific enolase), 105, 113**

**Nuclear magnetic resonance (NMR) of plasma lipids, 116**

## **O**

**Oncogenes and their products, 116-120**

**Opinions, 322-326, 368-371**

- Effects of irradiation on breast cancer and the breast, 368-371
- Narcotics and cancer pain control, 322-326

**Opioid analgesics, 327, 337-344**

- (See also, Narcotics and cancer pain control)
- Agonist class, 337, 339
- Agonist-antagonist class, 337, 339
- Dependence on, 342, 344
- Equianalgesic doses, 339, 340
- Guidelines for drug selection and dosing, 337-344
- Plasma half-life, 338-339
- Pure-agonist class, 337
- Routes of administration, 340, 343
- Side effects, 340-342
- Tolerance, 342

**Oral cancer**

- Incidence of, 5, 14, 16
- Mortality of, 5, 15, 17, 18
- And smokeless tobacco, use of, 224-225, 230-239, 241-243
- Survival rates, by race, 22

**Osteosarcoma**

- Survival rates for children, 21

**Ovarian cancer**

- And CA-125, use of, as tumor marker, 114-115
- Incidence of, 5, 7, 14
- Mortality of, 5, 9, 12, 15
- Survival rates for, by race, 6, 22



**Oxycodone**, 337, 338

**Oxyphenbutazone**, 335

## **P**

### **Pain control in the cancer patient**, 327-352

(See also, Opioid, and Adjuvant, analgesics; NSAIDs; and Narcotics and cancer pain control)

And pain complaint, classification of, 328-329

And deafferentation, 329

Etiologic, 329

And nociceptive focus, 328-329

Pathophysiologic, 329

Psychogenic, 329

Temporal, 328

Topographic, 328-329

Pain diagnosis guidelines, 328-333

Pain management, therapeutic and analgesic approaches to, 333-348

And adequacy of, 327-348

Anesthetic, 345, 346-347

Neuroaugmentative, 345, 347

Neurosurgical, 345, 347

Pharmacologic, 333-346

Physiologic, 347

Psychological, 348

And pain, nature of, 322-323, 327-328, 331-332

And the patient, classification of, 329-330

### **Palliation**

And neutron irradiation, 355-356

### **Pancreatic cancer**, 115, 268, 310-319

And CA 19-9, use of as tumor marker, 115

And chemotherapy, 315-316, 317

Diagnosis, 311

Epidemiology, 310-311

Hyperthermia with chemotherapy, 317

Incidence of, 5, 14, 16

Mortality of, 5, 9, 12, 13, 15, 17, 48, 52

And radiation therapy, 314-315

And neutron irradiation, 355-357

And surgery, 312-314

Survival rates, by race, 22

Tumor markers, 316-317

### **Pancreatoduodenectomy, (Whipple resection)** 312-314

### **PAP (prostatic acid phosphatase)**, 105-106, 109-110

### **Pap testing, ACS new checkpoint guideline recommendations for**, 127-128

### **Patient with pain, cancer, guidelines for assessment of**, 330-333

**Penis, cancer of**, 191-192 (letters)

**Pentazocine**, 337

### **Pharmacologic approaches to cancer pain management**, 322-326, 333-346

Adjuvant analgesics, 333, 344, 346

Anticonvulsants, 344

Antidepressants, tricyclic, 344

Corticosteroids, 346

Neuroleptics, 344

Cultural issues facing prescription of analgesics, 325-326

Dependency vs. addiction, 324, 342, 344

And drug laws and regulations, 325-327

Nonsteroidal anti-inflammatory drugs (NSAIDs), 334-336

Guidelines for drug selection and dosing, 334, 336

Opioid analgesics, 337-344

Guidelines for drug selection and dosing, 337-344

And oral medication for chronic pain, 323

And physician's prescription, 324-325

And respiration depression, effects on, 323-324, 341

### **Pharynx, cancer of**

Smoking and, 38-41, 43, 44, 51, 56

Survival rates for, by race, 22

**Phenybutazone**, 336

**Photon irradiation**, 355-360

### **Physiologic approaches to cancer pain management**, 347

**Piroxicam**, 336

**Pregnancy and smoking**, 207

**Projective identification (double-bind communication), and the cancer patient**, 149-152

**Prokaryotic cells**, 98

**Prophylactic intravesical therapy, and bladder tumors**, 218

**Propoxyphene**, 337

### **Prostate cancer**

Incidence of, 5, 7, 14, 16

Mortality of, 5, 9, 13, 15, 17, 19, 52

And neutron irradiation, 355, 360

Survival rates for, by race, 6, 22

**Prostate-specific antigen (See, PSA)**

**Prostatic acid phosphatase (See, PAP)**

**Prostatic hyperplasia**, 113

**Pruritus**, 61-62 (letters)  
Opioid analgesics and, 342

**PSA (prostate-specific antigen)**, 113

**Psychiatric treatment and cancer therapy**, 133-137

- Anxiety, relieving, 133-134
- Delirium, 135-136
- Depression, 136
- General guidelines of therapy, 133
- And pain management, 348
- Sleep disturbance, treating, 134-135

**Psychosexual dysfunction and breast cancer treatment**, 154-161

**Psychosocial issues and cancer**, 130-186

- Behavioral approaches to treatment-related distress, 138-145
- Most-significant-other in care of breast cancer patient, 146-153
- Parent self-help groups for families of children with cancer, 169-175
- Psychiatric treatment during cancer therapy, 133-137
- Role of self-help groups in helping patients and families cope with cancer, 162-168
- Sexual and intimate consequences of breast cancer treatment, 154-161
- Unorthodox cancer medicine, 176-186

**Pulmonary diseases**  
(See also, Lung cancer)  
Smoking and, 28-60

## R

**Radiography, digital breast**, 61 (correction)

**Radioimaging**, 79, 82, 108

**Radiotherapy**, 272, 333, 368-371  
And bladder cancer, 213, 217, 219  
Effects of, on breast cancer and the breast (opinion), 368-371  
Neutron beam therapy and nonresectable radioresistant tumors, 353-361  
Clinical data, 354-356  
Effects on normal tissue and cell renewal systems, 355  
Neutrons vs. photons, 355-360  
Pancreatic cancer and, 314-316  
For sacrococcygeal teratomas, 365-366

**Rectum, cancer of**

- Incidence of, 5, 7, 14, 16
- Mortality of, 5, 9, 12, 13, 15, 17, 18

Smoking and, 48, 52  
Survival rates for, by race, 6, 22

**Relaxation training, for control of anticipatory nausea and vomiting**, 140

**Renal cancer**

- Interferon and, 266-268
- Survival rates for, by race, 22

**Resection, transurethral and segmental, and bladder tumors**, 218

**Respiratory system, cancer of**

- (See also specific respiratory organs)
- Incidence of, 14
- Mortality of, 15

**Reticulosarcoma, and smoking**, 48, 52

**Retinoblastoma**

- Survival rates for children, 21

**Rhabdomyosarcoma**

- Survival rates for children, 21

## S

**Sacrococcygeal teratomas**, 362-367  
See also, Teratomas, Sacrococcygeal

**Salivary gland tumors and neutron irradiation**, 354-360

**Salsalate**, 336

**Schistosomiasis and bladder cancer**, 213

**Screening, mammography, pilot project**, 291-309

**Self-help groups and cancer**, 162-168, 169-175

- Effectiveness of, studies in, 165-166
- Evolution and development of, 163
- And health care providers, role of, 167
- Parent, for families of children with cancer, 169-175
- Processes, in self-help groups, 166-167
- And professional help, 162-163
- Scope of groups, 164
- TOUCH program, 163-164

**Sexual and intimate consequences of breast cancer treatment**, 154-161

**Sexual response and cancer**, 190-191 (letters)

**Skin cancer**  
See, Melanoma

**Smokeless tobacco**, 224-225, 226-229, 230-235, 236-243, 244-247, 248-256  
And cancer, the epidemiologic evidence, 236-243  
Carcinogenesis, role of viral and other factors, 248-256  
HSV inactivation by snuff, 249-252  
HSV and snuff, combined effect of, on cellular oncogenes, 252-254  
Health effects of (symposium proceedings), 224-225  
Nature of, 226-227  
Nicotine and, 244-247  
Oral mucosal lesions in users of, 230-235  
Users of, 227-229

**Smoking**  
Bladder cancer and, 213  
Cigarette smoking, and exposure to asbestos, 26  
Cigarette smoking, and the need for action by health professionals, 194-212  
Cessation advice, overview and contents of, 196-206  
Cessation, and physician's and medical staff's role, 195-196, 206-210  
And children and adolescents, preventing initiation by, 206-210  
Involuntary, health consequences of, 194  
NCI's goals for year 2000, 194  
And death rates (classic), 28-58  
Evidence and ethics (Remarks), 59-60  
Pancreatic cancer and, 310-311

**Snuff** (See, Smokeless tobacco)

**Soft tissue sarcomas**  
Survival rates for children, 21  
Treated by neutrons, 354-355, 358-359

**Splanchicectomy, chemical**  
Use of, to control pancreatic pain, 314

**Statistics, cancer**, 5-22  
(See also, Mortality; specific cancer sites)

**Stomach cancer**  
Incidence, 7, 14  
Mortality of, 9, 12, 13, 15, 19  
Smoking and, 48, 52  
Survival rates for, by race, 6, 22

**Sulindac**, 336

**Sympathetic nervous system, cancer of**  
Survival rates for children, 21

**Systematic desensitization, and control of anticipatory nausea and vomiting**, 140-141

## T

**TA-4 (tumor-associated antigen)**, 115

**Teratomas, sacrococcygeal**, 362-367  
Definition, 362  
Diagnosis, 362-363  
During maternal ultrasonography, 362  
Pathology, 363-364  
Prognosis, 366  
And serum alphafetoprotein as tumor marker, 366  
Signs and symptoms, 362-363  
Treatment of, 364-365

**Testis, cancer of**  
Incidence of, 7, 14  
Mortality of, 15  
Survival rates for, by race, 6, 22  
And tumor markers, use of, 108

**Tetrahydrocannabinol**, 346

**Thrombocytopenia**, 62-63 (letters)

**Thyroid, cancer of**  
Incidence of, 14  
Mortality of, 15  
Survival rates for, by race, 22  
And tumor markers, use of, 108

**Tobacco**  
(See also, Smokeless tobacco, Smoking)

**Tongue cancer**  
Smoking and, 38-41, 43, 44, 51, 56

**TOUCH program (Today Our Understanding of Cancer is Hope)**, 163-164

**TNF** (See, Tumor Necrosis Factor)

**Treatment, cancer**  
(See also, Pain control in the cancer patient)  
Coping with treatment-related problems, 61-64 (letters)  
Distress caused by, behavioral approaches for, 138-145  
Immunologic, 68-94  
Of radioresistant tumors, 353-361  
Unorthodox, 176-186

**Tumor-associated antigen** (See, TA-4)

**Tumor classification, bladder, 214-215**

**Tumor markers, 104-126**

Categories of, 105-106, 109

In clinical use, 106-110, 111

Defining, 104-105

Of general applicability, 116-120

New, for specific cancers, 113-115

New, tumor-associated, 115-116

Pancreatic cancer and, 316-317

Serum, in diagnosis and prognosis,  
110-113, 366

Serum, strategies for use of, 120-121

**Tumor necrosis factor (TNF), 68, 115, 262**

## U

**Ulcers**

Gastric and duodenal, smoking and,  
31-34, 55, 57

NSAIDs and, 336

**Ultrasonography and pancreatic cancer,  
311**

**Unorthodox cancer medicine, 176-186**

And the clinician, suggestions for, 183-184

Current unproven therapies, 178-181

Who seeks and who dispenses it, 181-183

**Urinary cancer**

Incidence of, 5, 14

Mortality of, 5, 15

Smoking, and genitourinary system,  
cancer of, 38-41, 43, 44, 57

**Uterine cancer**

Incidence of, 5, 7, 14, 16

Mortality of, 5, 9, 12, 15, 17, 19

Survival rates for, by race, 6, 22

## V

**Vaccines, 68, 71**

Development of, 98-102

**Vaginal lubricants, and breast cancer  
patients, 158**

**Vinblastine, 72**

**Vincristine, 72**

**Viral infections associated with human  
cancer, immunization against, 95-103**

Infectious agents, biology of, 95-98

And vaccines, development of, 98-102

**VZV (varicella zoster virus), 96**

## W

**Whipple resection**

(pancreatoduodenectomy), 312-314

**Wilms' tumor**

Survival rates for children, 21

## X

**Xerostomia, 62-63 (letters)**

# Author Index, 1988

## Vol. 38, Nos. 1-6

### A

---

Ahmad A, 188 (letter)  
Akoto-Amanfu E, 248-256  
Althausen AF, 191  
Arlington A, 187-188 (letter)

### B

---

Baum LS, 61 (letter)  
Beazley RM, 310-319  
Benowitz NL, 244-247  
Braddock SW, 61-62 (letter)  
Brown H, 176-186

### C

---

Cassileth BR, 176-186  
Cohn I, Jr., 310-319

### D

---

Doff RS, 62 (letter)

### E

---

Eberle B, 61 (letter)

### F

---

Fink DJ, 127-128  
Friedman N, 368-371  
Friedman RH, 62 (letter)

### G

---

Gage AA, 189 (letter)  
Garfinkel L, 23-27 (classic)  
Gates CC, 146-153  
Goldstein D, 258-277  
Gritz ER, 194-212

### H

---

Hammond EC, 28-60 (classic)  
Harnsberger HR, 189-190 (letter)  
Hendrickson FR, 353-361  
Herberman RB, 104-126  
Hilderley L, 61 (letter)  
Hill CS, Jr., 322-326  
Holland J, 130-132  
Holleb AI, 2-4 (editorial)  
Holmstrup P, 230-235  
Hopkins KP, 63-64 (letter)  
Horn D, 28-58 (classic)

### I

---

Isaacs A, 280-290 (classic)

### L

---

Lasky HJ, 291-309  
Laszlo J, 258-277  
Levy GR, 62-63 (letter)  
Lewis JS, 188-189 (letter)  
Lieberman MA, 162-168  
Lindenmann J, 278-290 (classic)  
Lotze MT, 68-94  
Lubera JA, 5-22

### M

---

Maher ML, 291-309  
Mahour GH, 362-367  
Meignier B, 95-103  
Mercer DW, 104-126  
Monaco GP, 169-175

### O

---

Ohl DA, 190 (letter)

## **P**

---

Paik DI, 248-256  
Park N-H, 248-256  
Persky L, 192 (letter)  
Pindborg JJ, 230-235  
Plocher DW, 189 (letter)  
Portenoy RK, 327-352

## **R**

---

Rauscher FJ, Jr., 66-67  
Redd WH, 138-145  
Roizman B, 95-103  
Rosenberg SA, 68-94

## **S**

---

Schain WS, 154-161  
Silberfarb PM, 133-137

Silverberg E, 5-22  
Squier CA, 224-229  
Sylvester J, 291-309

## **T**

---

Tuttle JP, 190-191 (letter)

## **V**

---

Vaughn CG, 62 (letter)  
Virji MA, 104-126

## **W**

---

Wagner RF, Jr., 191-192 (letter)  
Weissmann C, 278-279 (classic)  
Wellisch D, 130-132  
Whitmore WF, Jr., 213-223  
Winchester DP, 291-309  
Winn DM, 236-243

